Jabodon PT Co’s Cytokinetics CYTK Stock Holding History

Jabodon PT Co’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-65,459	Closed	-$2.41M	–	10
2022 Q1	$2.41M	Sell	65,459 -2,836	-4%	-$101K	1.09%	25
2021 Q4	$3.11M	Buy	+68,295	New	+$2.64M	1.42%	24

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Jabodon PT Co's CYTK Position: Q2 2022 in Review

Jabodon PT Co sold out of Cytokinetics (CYTK) in Q2 2022, closing a stake of 65,459 shares — an estimated $2.41M sold.

Jabodon PT Co first reported a position in CYTK in Q4 2021 and held it in 2 quarters. The position peaked at $3.11M in Q4 2021. 262 funds tracked by Wall St. Rank hold CYTK as of Q2 2022.

Jabodon PT Co reported no remaining Cytokinetics position as of Q2 2022 after selling out during the quarter.
Jabodon PT Co sold 65,459 Cytokinetics shares in Q2 2022, an estimated $2.41M.
Jabodon PT Co first reported a position in Cytokinetics in Q4 2021 and held it in 2 quarters.
Jabodon PT Co's Cytokinetics position peaked at $3.11M in Q4 2021.
262 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2022.

Based on Jabodon PT Co's 13F filing for Q2 2022, filed 12 Aug 2022.